TIDMBXP
RNS Number : 4121S
Beximco Pharmaceuticals Ltd
06 November 2023
6 November 2023
This announcement contains inside information as stipulated
under the UK version of the Market Abuse Regulation 596/2014 which
is part of English Law by virtue of the European (Withdrawal) Act
2018, as amended. On publication of this announcement via a
regulatory information service, this information is considered to
be in the public domain.
BEXIMCO PHARMACEUTICALS LIMITED
Financial Results for the First Quarter Ended 30 September
2023
Beximco Pharmaceuticals Limited ("Beximco Pharma", "BPL" or "the
Company"; AIM Symbol: BXP, LEI No.:213800IMBBD6TIOQGB56), the
fast-growing manufacturer of generic pharmaceutical products and
active pharmaceutical ingredients, today announces its unaudited
results for the three-month period ended 30 September 2023. The
information set out below has been released to the Dhaka and
Chittagong Stock Exchanges in compliance with the requirements from
the Bangladesh SEC.
Beximco Pharma Managing Director Nazmul Hassan MP commented:
"Amidst challenges, we delivered strong growth in revenue in
this first quarter. The ongoing macro-economic headwinds,
especially the devaluation of currency and high inflationary
pressures, weigh on our bottom line and somewhat overshadow our
accomplishment. That said, we remain confident in the strength of
the business and our strategy as we continue to focus on growth
through the delivery of high-quality, affordable medicines to
patients."
The detailed accounts can be viewed at the Company website: www.beximcopharma.com
For further information please visit www.beximcopharma.com or
enquire to:
Beximco Pharma
Nazmul Hassan MP, Managing Director
Tel: +880 2 586/11001, Ext.20080
S M Rabbur Reza, Chief Operating Officer
Tel: +880 2 58611001, Ext.20111
Mohammad Ali Nawaz, Chief Financial Officer
Tel: +880 2 58611001, Ext.20030
SPARK Advisory Partners Limited (Nominated Adviser)
Mark Brady / Andrew Emmott
Tel: +44 (0) 20 3368 3551 / 3555
SP Angel Corporate Finance LLP (Broker)
Matthew Johnson
Tel: +44 (0) 20 3470 0470
FTI Consulting
Simon Conway / Victoria Foster Mitchell
Tel: +44 (0) 20 3727 1000
Notes to Editors
About Beximco Pharmaceuticals Limited
Beximco Pharma is a leading manufacturer and exporter of
medicines based in Bangladesh. Since its inception in 1976, the
Company remains committed to health and wellbeing of people across
all the continents by providing access to contemporary medicines.
Company's broad portfolio of generics encompasses diverse delivery
systems such as tablets, capsules, liquids, semi-solids,
intravenous fluids, metered dose inhalers, dry powder inhalers,
sterile ophthalmic drops, insulins, prefilled syringes,
injectables, nebuliser solutions, oral soluble films etc. The
Company also undertakes contract manufacturing for multinational
and leading global generic pharmaceutical companies.
Beximco Pharma's state-of-the-art manufacturing facilities are
certified by global regulatory authorities of USA, Europe,
Australia, Canada, GCC and Latin America, among others and it has a
geographic footprint in more than 50 countries. More than 5,500
employees are driving the company towards achieving its aspiration
to be among the most admired companies in the world.
Beximco Pharmaceuticals Limited and its Subsidiaries
Consolidated Statement of Financial Position (Un-audited)
As at September 30, 2023
Taka '000
September June 30,
30, 2023 2023
ASSETS
Non-Current Assets 48,409,531 48,280,929
Property, Plant and Equipment- Carrying
Value 42,356,471 42,245,615
Right-of-use Assets 538,197 562,224
Intangible Assets 4,766,816 4,721,035
Deferred Tax Asset 52,504 56,512
Goodwill 674,570 674,570
Other Investments 20,973 20,973
Current Assets 20,942,045 20,875,854
Inventories 11,958,465 12,133,278
Spares & Supplies 888,249 819,740
Accounts Receivable 3,671,221 3,574,655
Loans, Advances and Deposits 3,049,766 2,984,877
Advance Income Tax 230,467 227,618
Short Term Investment 200,000 -
Cash and Cash Equivalents 943,877 1,135,686
---------- ----------
TOTAL ASSETS 69,351,576 69,156,783
---------- ----------
SHAREHOLDERS' EQUITY AND LIABILITIES
Equity Attributable to the Owners of
the Company 45,233,894 43,680,704
Issued Share Capital 4,461,121 4,461,121
Share Premium 5,269,475 5,269,475
Excess of Issue Price over Face Value
of GDRs 1,689,637 1,689,637
Capital Reserve on Merger 294,951 294,951
Revaluation Surplus 1,140,210 1,141,178
Unrealized Gain/(Loss) 18,148 18,148
Retained Earnings 32,360,352 30,806,194
Non-Controlling Interest 3,953,454 3,938,962
TOTAL EQUITY 49,187,348 47,619,666
Non-Current Liabilities 8,383,552 8,272,093
Long Term Borrowings-Net of Current
Maturity 2,306,715 2,550,833
Liability for Gratuity, Pension and
WPPF & Welfare Funds 3,535,080 3,170,764
Deferred Tax Liability 2,541,757 2,550,496
Current Liabilities and Provisions 11,780,676 13,265,024
Short Term Borrowings 4,732,715 6,621,170
Long Term Borrowings-Current Maturity 1,468,445 1,439,895
Creditors and Other Payables 3,706,475 3,531,707
Accrued Expenses 1,032,588 1,129,700
Dividend Payable / Unclaimed Dividend 88,235 88,465
Income Tax Payable 752,218 454,087
---------- ----------
TOTAL EQUITY AND LIABILITIES 69,351,576 69,156,783
---------- ----------
Beximco Pharmaceuticals Limited and its Subsidiaries
Consolidated Statement of Profit or Loss and Other Comprehensive
Income (Un-audited)
For the Period July - September 2023
Taka '000
July -September July -September
2023 2022
Net Revenue 11,159,367 9,787,202
Cost of Goods Sold (6,251,512) (5,351,036)
--------------- ---------------
Gross Profit 4,907,855 4,436,166
--------------- ---------------
Operating Expenses (2,598,458) (2,313,283)
--------------- ---------------
Administrative Expenses (304,684) (274,747)
Selling, Marketing and Distribution
Expenses (2,293,774) (2,038,536)
--------------- ---------------
Profit from Operations 2,309,397 2,122,883
Other Income 144,875 168,042
Finance Cost (297,754) (310,973)
Profit Before Contribution to WPPF
& Welfare Funds 2,156,518 1,979,952
Contribution to WPPF & Welfare Funds (103,572) (98,210)
--------------- ---------------
Profit Before Tax 2,052,946 1,881,742
Income Tax Expenses (485,545) (469,029)
--------------- ---------------
Current Tax (489,995) (393,848)
Deferred Tax 4,450 (75,181)
--------------- ---------------
Profit After Tax 1,567,401 1,412,713
Profit/(Loss) Attributable to:
--------------- ---------------
Owners of the Company 1,552,909 1,447,027
Non-Controlling Interest 14,492 (34,314)
--------------- ---------------
1,567,401 1,412,713
Other Comprehensive Income/(Loss) - (3,340)
--------------- ---------------
Total Comprehensive Income 1,567,401 1,409,373
Total Comprehensive Income Attributable
to:
--------------- ---------------
Owners of the Company 1,552,909 1,443,687
Non-Controlling Interest 14,492 (34,314)
--------------- ---------------
1,567,401 1,409,373
=============== ===============
Earnings Per Share
(EPS) Tk. 3.48 3.24
=============== ===============
Number of Shares Nos. 446,112,089 446,112,089
Beximco Pharmaceuticals Limited and its Subsidiaries
Consolidated Statement of Changes in Equity (Un-audited)
For the Period July - September 2023
As at September 30, 2023
Taka '000
----------------------------------------------------------------------------------------------------------------------------------------
Share Share Excess Capital Revaluation Unrealized Retained Equity Non- Total
Capital Premium of Issue Reserve Surplus Gain/ Earnings attributable Controlling Equity
Price on Merger (Loss) to Owners Interests
over of the
Face Company
Value
of GDRs
--------- --------- --------- --------- ------------- ---------- ---------- ------------ ----------- ----------
Balance
as on July
01, 2023 4,461,121 5,269,475 1,689,637 294,951 1,141,178 18,148 30,806,194 43,680,704 3,938,962 47,619,666
--------- --------- --------- --------- ------------- ---------- ---------- ------------ ----------- ----------
Total
Comprehensive
Income:
------------------------------------------------------------------------------------------------------------------------
Profit/(Loss)
for the
Period - - - - - - 1,552,909 1,552,909 14,492 1,567,401
--------- --------- --------- --------- ------------- ---------- ---------- ------------ ----------- ----------
Other - - - - - - - - - -
Comprehensive
Income/(Loss)
--------- --------- --------- --------- ------------- ---------- ---------- ------------ ----------- ----------
Adjustment
for
Depreciation
on Revalued
Assets - - - - (1,249) - 1,249 - - -
--------- --------- --------- --------- ------------- ---------- ---------- ------------ ----------- ----------
Adjustment
for Deferred
Tax on
Revalued
Assets - - - - 281 - - 281 - 281
--------- --------- --------- --------- ------------- ---------- ---------- ------------ ----------- ----------
Balance
as on
September
30, 2023 4,461,121 5,269,475 1,689,637 294,951 1,140,210 18,148 32,360,352 45,233,894 3,953,454 49,187,348
--------- --------- --------- --------- ------------- ---------- ---------- ------------ ----------- ----------
Net Asset Value
(NAV) Per Share Tk. 101.40
------------------------- --------- -------------- ------------ ----------------- ---------- ------------ ----------- ----------
As at September 30, 2022
------------------------------------------------------------------------------------------------------------------------------------
Share Share Excess Capital Revaluation Unrealized Retained Equity Non- Total
Capital Premium of Issue Reserve Surplus Gain/ Earnings attributable Controlling Equity
Price on (Loss) to Owners Interests
over Merger of the
Face Company
Value
of GDRs
--------- --------- --------- ------- ----------- ---------- ---------- ------------ ----------- ----------
Balance
as on July
01, 2022 4,461,121 5,269,475 1,689,637 294,951 1,116,896 20,532 27,747,886 40,600,498 4,035,507 44,636,005
--------- --------- --------- ------- ----------- ---------- ---------- ------------ ----------- ----------
Total
Comprehensive
Income:
--------------------------------------------------------------------------------------------------------------------
Profit/(Loss)
for the
Period - - - - - - 1,447,027 1,447,027 (34,314) 1,412,713
--------- --------- --------- ------- ----------- ---------- ---------- ------------ ----------- ----------
Other
Comprehensive
Income/(Loss) - - - - - (3,340) - (3,340) - (3,340)
--------- --------- --------- ------- ----------- ---------- ---------- ------------ ----------- ----------
Adjustment
for
Depreciation
on Revalued
Assets - - - - (1,409) - 1,409 - - -
--------- --------- --------- ------- ----------- ---------- ---------- ------------ ----------- ----------
Adjustment
for Deferred
Tax on
Revalued
Assets - - - - 317 - - 317 - 317
--------- --------- --------- ------- ----------- ---------- ---------- ------------ ----------- ----------
Balance
as on
September
30, 2022 4,461,121 5,269,475 1,689,637 294,951 1,115,804 17,192 29,196,322 42,044,502 4,001,193 46,045,695
--------- --------- --------- ------- ----------- ---------- ---------- ------------ ----------- ----------
Net Asset Value (NAV)
Per Share Tk. 94.25
------------------------------------ --------- ------- ----------- ---------- ---------- ------------ ----------- ----------
Beximco Pharmaceuticals Limited and its Subsidiaries
Consolidated Statement of Cash Flows (Un-audited)
For the Period July - September 2023
Taka '000
July -September July -September
2023 2022
Cash Flows from Operating Activities:
--------------- ---------------
Receipts from Customers and Others 11,197,080 9,853,354
Payments to Suppliers and Employees (7,998,606) (8,584,421)
--------------- ---------------
Cash Generated from Operations 3,198,474 1,268,933
Interest Paid (295,410) (310,322)
Interest Received - 1,310
Income Tax Paid (194,713) (275,443)
Net Cash Generated from Operating Activities 2,708,351 684,478
Cash Flows from Investing Activities:
--------------- ---------------
Acquisition of Property, Plant and Equipment (513,160) (636,985)
Intangible Assets (97,638) (45,431)
Disposal of Property, Plant and Equipment 3,488 20
Disposal of Intangible Assets - 52,125
Short Term Investment (200,000) -
Net Cash Used in Investing Activities (807,310) (630,271)
Cash Flows from Financing Activities:
--------------- ---------------
Net Increase /(Decrease) in Long Term
Borrowings (211,318) (619,541)
Net Increase/(Decrease) in Short Term
Borrowings (1,888,455) 256,464
Dividend Paid (231) (295)
--------------- ---------------
Net Cash (Used in) / from Financing
Activities (2,100,004) (363,372)
Increase/(Decrease) in Cash and Cash
Equivalents (198,963) (309,165)
Cash and Cash Equivalents at Beginning
of Period 1,135,686 1,168,674
Effect of Exchange Rate Changes on Cash
and Cash Equivalents 7,154 13,144
--------------- ---------------
Cash and Cash Equivalents at End of
Period 943,877 872,653
Number of Shares 446,112,089 446,112,089
Net Operating Cash Flows Per Share 6.07 1.53
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
QRFFLFVRLRLEIIV
(END) Dow Jones Newswires
November 06, 2023 02:00 ET (07:00 GMT)
Beximco Pharma (LSE:BXP)
Historical Stock Chart
From Oct 2024 to Nov 2024
Beximco Pharma (LSE:BXP)
Historical Stock Chart
From Nov 2023 to Nov 2024
